LENZ Therapeutics (LENZ) Total Current Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Current Liabilities data on file, last reported at $25.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 201.16% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (up 201.16% YoY) and the FY2025 annual result came in at $21.2 million, up 103.6% from the prior year.
• Total Current Liabilities improved to $25.8 million in Q1 2026 per LENZ's latest filing, from $21.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $25.8 million in Q1 2026 and bottomed at $7.7 million in Q3 2024.
• The 5-year median for Total Current Liabilities is $12.8 million (2022), against an average of $13.9 million.
• The widest annual swing landed in 2025, when Total Current Liabilities plunged 54.63%; it then jumped 201.16% in 2026.
• Tracing LENZ's Total Current Liabilities over 5 years: stood at $13.0 million in 2022, then soared by 41.95% to $18.5 million in 2023, then slumped by 43.79% to $10.4 million in 2024, then soared by 103.6% to $21.2 million in 2025, then increased by 21.8% to $25.8 million in 2026.
• Per Business Quant, the three latest LENZ Total Current Liabilities figures stand at $25.8 million (Q1 2026), $21.2 million (Q4 2025), and $16.3 million (Q3 2025).

Peer Comparison